Showing 2281-2290 of 4065 results for "".
Optimizing VNS Parameters: Keys to Therapeutic Success
https://reachmd.com/programs/cme/optimizing-vns-parameters-keys-to-therapeutic-success/35797/Tune in to learn about using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) & treatment-resistant depression (TRD).The Role of Multidisciplinary Care in LGMD2I/R9
https://reachmd.com/programs/cme/the-role-of-multidisciplinary-care-in-lgmd2ir9/35880/Learn about LGMD2I/R9—genetics, diagnosis, treatment, clinical trials, and care gaps—in this expert-led, comprehensive educational video series.Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
https://reachmd.com/programs/cme/redefining-ohcm-care-efficacy-and-safety-of-myosin-inhibitors/54840/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
https://reachmd.com/programs/cme/from-evidence-to-action-integrating-emerging-myosin-inhibitors-into-ohcm-treatment-plans/54841/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Muscarinic Therapies as a Catalyst for Change: Addressing Clinical Inertia in Schizophrenia Care
https://reachmd.com/programs/cme/muscarinic-therapies-as-a-catalyst-for-change-addressing-clinical-inertia-in-schizophrenia-care/37101/Examine muscarinic modulation as an alternative to D2 antagonists for schizophrenia, with insights on dosing, tolerability, and patient selection.When ß-Blockers Fall Short in oHCM: Time for a New Approach?
https://reachmd.com/programs/cme/when-blockers-fall-short-in-ohcm-time-for-a-new-approach/54838/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Inside the 4 Hits: Targeting APRIL to Change the Course of IgAN
https://reachmd.com/programs/cme/inside-the-4-hits-targeting-april-to-change-the-course-of-igan/48815/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Continuity in Care: Strategies for Managing Growth Hormone Deficiency Through Life’s Stages
https://reachmd.com/programs/cme/continuity-in-care-strategies-for-managing-growth-hormone-deficiency-through-lifes-stages/35523/Continuity in Care: Strategies for Managing Growth Hormone Deficiency Through Life’s StagesApplying Evidence to Clinical Practice
https://reachmd.com/programs/cme/applying-evidence-to-clinical-practice/36183/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Molecular Precision: How Myosin Inhibitors Redefine Control
https://reachmd.com/programs/cme/molecular-precision-how-myosin-inhibitors-redefine-control/54839/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.